Septerna, Inc. (NASDAQ:SEPN) is Trv Gp Vi LLC's Largest Position

Key Points

• Trv Gp Vi LLC has increased its stake in Septerna, Inc. by 33.6%, now holding approximately 9.46% of the company valued at about $24.39 million.
• Septerna reported a quarterly earnings loss of ($0.49) EPS, below the consensus estimate of ($0.38), and forecasts suggest an annual EPS of -7.11.
• Analysts have set a new average target price of $26.75 for Septerna, with several firms recently upgrading their ratings and target prices significantly.

TRV GP VI LLC grew its position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) by 33.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,211,659 shares of the company's stock after purchasing an additional 1,059,203 shares during the quarter. Septerna makes up about 58.1% of TRV GP VI LLC's holdings, making the stock its largest position. TRV GP VI LLC owned 9.46% of Septerna worth $24,386,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in shares of Septerna during the fourth quarter worth about $1,803,000. JPMorgan Chase & Co. acquired a new stake in shares of Septerna during the fourth quarter worth about $871,000. Jane Street Group LLC acquired a new stake in shares of Septerna during the fourth quarter worth about $600,000. MetLife Investment Management LLC acquired a new stake in shares of Septerna during the fourth quarter worth about $265,000. Finally, Barclays PLC acquired a new stake in Septerna in the fourth quarter valued at about $659,000.

Septerna Trading Down 0.6%

Shares of SEPN traded down $0.07 during mid-day trading on Monday, reaching $11.62. 33,059 shares of the company's stock were exchanged, compared to its average volume of 697,865. The company has a 50-day simple moving average of $11.38 and a two-hundred day simple moving average of $9.29. Septerna, Inc. has a 52-week low of $4.17 and a 52-week high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter. Equities analysts forecast that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald raised their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. HC Wainwright began coverage on shares of Septerna in a report on Monday, June 23rd. They issued a "buy" rating and a $26.00 target price for the company. Finally, Wells Fargo & Company increased their target price on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $26.75.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.